Literature DB >> 21473915

Intensity of macrolide anti-inflammatory activity in J774A.1 cells positively correlates with cellular accumulation and phospholipidosis.

Vesna Munić1, Mihailo Banjanac, Sanja Koštrun, Krunoslav Nujić, Martina Bosnar, Nikola Marjanović, Jovica Ralić, Mario Matijašić, Mario Hlevnjak, Vesna Eraković Haber.   

Abstract

Some macrolide antibiotics were reported to inhibit interleukin-6 (IL6) and prostaglandin-E2 (PGE(2)) production by bacterial lipopolysaccharide (LPS) stimulated J774A.1 cells. Macrolides are also known to accumulate in cells and some were proven inducers of phospholipidosis. In the present study, with a set of 18 mainly 14- and 15-membered macrolides, we have investigated whether these macrolide induced phenomena in J774A.1 cells are connected. In LPS-stimulated J774A.1 cells, the extent of inhibition of proinflammatory markers (IL6 and PGE(2)) by macrolides significantly correlated with their extent of accumulation in cells, as well as with the induction of phospholipidosis, and cytotoxic effects in prolonged culture (with correlation coefficients (R) ranging from 0.78 to 0.93). The effects observed were related to macrolide binding to phospholipids (CHI IAM), number of positively charged centres, and were inversely proportional to the number of hydrogen bond donors. Similar interdependence of effects was obtained with chloroquine and amiodarone, whereas for dexamethasone and indomethacin these effects were not linked. The observed macrolide induced phenomena in J774A.1 cells were reversible and elimination of the macrolides from the culture media prevented phospholipidosis and the development of cytotoxicity in long-term cultures. Based on comparison with known clinical data, we conclude that LPS-stimulated J774A.1 cells in presented experimental setup are not a representative cellular model for the evaluation of macrolide anti-inflammatory potential in clinical trials. Nevertheless, our study shows that, at least in in vitro models, binding to biological membranes may be the crucial factor of macrolide mechanism of action. 2011 Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21473915     DOI: 10.1016/j.phrs.2011.03.011

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  11 in total

1.  Azithromycin distinctively modulates classical activation of human monocytes in vitro.

Authors:  M Vrančić; M Banjanac; K Nujić; M Bosnar; T Murati; V Munić; D Stupin Polančec; D Belamarić; M J Parnham; V Eraković Haber
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 2.  Azithromycin use in patients with cystic fibrosis.

Authors:  N Principi; F Blasi; S Esposito
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-02-17       Impact factor: 3.267

3.  One man's poison is another man's meat: using azithromycin-induced phospholipidosis to promote ocular surface health.

Authors:  Yang Liu; Wendy R Kam; Juan Ding; David A Sullivan
Journal:  Toxicology       Date:  2014-03-06       Impact factor: 4.221

4.  Tulathromycin exerts proresolving effects in bovine neutrophils by inhibiting phospholipases and altering leukotriene B4, prostaglandin E2, and lipoxin A4 production.

Authors:  Carrie D Fischer; Stephanie C Duquette; Bernard S Renaux; Troy D Feener; Douglas W Morck; Morley D Hollenberg; Merlyn J Lucas; Andre G Buret
Journal:  Antimicrob Agents Chemother       Date:  2014-05-12       Impact factor: 5.191

Review 5.  Pathogen- and host-directed anti-inflammatory activities of macrolide antibiotics.

Authors:  Helen C Steel; Annette J Theron; Riana Cockeran; Ronald Anderson; Charles Feldman
Journal:  Mediators Inflamm       Date:  2012-06-21       Impact factor: 4.711

6.  Killing of Staphylococcus aureus in murine macrophages by chloroquine used alone and in combination with ciprofloxacin or azithromycin.

Authors:  Somrita Dey; Biswadev Bishayi
Journal:  J Inflamm Res       Date:  2015-01-22

7.  Macrolide derivatives reduce proinflammatory macrophage activation and macrophage-mediated neurotoxicity.

Authors:  Bei Zhang; Timothy J Kopper; Xiaodong Liu; Zheng Cui; Steven G Van Lanen; John C Gensel
Journal:  CNS Neurosci Ther       Date:  2019-01-24       Impact factor: 5.243

8.  Bitter Taste Receptors (TAS2Rs) in Human Lung Macrophages: Receptor Expression and Inhibitory Effects of TAS2R Agonists.

Authors:  Stanislas Grassin-Delyle; Hélène Salvator; Nikola Mantov; Charlotte Abrial; Marion Brollo; Christophe Faisy; Emmanuel Naline; Louis-Jean Couderc; Philippe Devillier
Journal:  Front Physiol       Date:  2019-10-02       Impact factor: 4.566

9.  QSAR Models for Predicting Five Levels of Cellular Accumulation of Lysosomotropic Macrocycles.

Authors:  Ulf Norinder; Vesna Munic Kos
Journal:  Int J Mol Sci       Date:  2019-11-26       Impact factor: 5.923

10.  Azithromycin Affords Neuroprotection in Rat Undergone Transient Focal Cerebral Ischemia.

Authors:  Diana Amantea; Francesco Petrelli; Rosaria Greco; Cristina Tassorelli; Maria Tiziana Corasaniti; Paolo Tonin; Giacinto Bagetta
Journal:  Front Neurosci       Date:  2019-11-26       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.